contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


paxman-publishes-newsletter-on-that-a-sustained-medicare-payment-rate-for-scalp-cooling-is-proposed-for-2023

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Paxman

Today, Paxman publishes the August issue of its newsletter aimed at shareholders, investors and other interested parties.This month’s issue highlights that Centers for Medicare & Medicaid Services...

<div class="mfn-preamble"><p><strong>Today, Paxman publishes the August issue of its newsletter aimed at shareholders, investors and other interested parties.</strong></p></div><div class="mfn-body"><p>This month’s issue highlights that Centers for Medicare &amp; Medicaid Services (CMS) in the United States has proposed Medicare payment rates for hospital outpatient and Ambulatory Surgical Center (ASC) services for the calendar year 2023. If the proposed rule is finalized without changes, this would mean that scalp cooling treatments billed with the CPT code 0662T will continue to have a payment rate of 1,850.50 USD. The final rule will be issued in early November.</p><p>The newsletter also includes information on that Paxman Scalp Cooling is available at 6 of the 10 top U.S. cancer hospitals, orders from locations in eight states in the US, several customers in the UK as well as from France, Schweiz and Singapore, the launch of Paxman’s PSCS system in Japan and that the company’s distributors in Colombia and Singapore received market clearance for Paxman Scalp Cooling from each country’s respective regulatory agency in charge of medical devices.</p><p>To read the newsletter and subscribe for upcoming issues, follow this link:</p><p><a rel="nofollow noopener" href="https://bit.ly/paxaug22en">https://bit.ly/paxaug22en</a></p><p>Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency <a rel="nofollow noopener" href="https://honeybadger.se/?lang=en">Honeybadger</a>. Every published issue of the newsletter is available on Paxman’s website for investors, <a rel="nofollow noopener" href="http://www.paxman.se/">www.paxman.se</a>. The company encourages feedback and requests on topics for upcoming issues of the newsletter. <br><br><strong>For more information, please contact:</strong><br>Richard Paxman, CEO<br>Tel: +44 7968 020641<br>Email: richard@paxmanscalpcooling.com<br>www.paxman.se</p></div><div class="mfn-footer mfn-contacts mfn-2b75fe265c03"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Richard Paxman, CEO  <br>Tel: +44 7968 020641  <br>Email: richard@paxmanscalpcooling.com <br><a rel="nofollow noopener" href="http://www.paxman.se">www.paxman.se</a></p></div><div class="mfn-footer mfn-about mfn-b1f5e09eeff2"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,400 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).</p><p>The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8&nbsp;528&nbsp;003 99.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/a4b5b5f0-ccb9-48ec-8412-1efa71835635/paxman-publishes-newsletter-on-that-a-sustained-medicare-payment-rate-for-scalp-cooling-is-proposed-for-2023.pdf" class="mfn-generated mfn-primary">Paxman publishes newsletter on that a sustained Medicare payment rate for scalp cooling is proposed for 2023</a></p></div>

Paxman publishes newsletter on that a sustained Medicare payment rate for scalp cooling is proposed for 2023